SCHEMBL25552004

SCHEMBL25552004

Cc1cnc(Cl)nc1-c1ccccc1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MBNL1 Q9NR56 1/20 0.51
PDK1 Q15118 1/20 0.43
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 2/20 0.41
NPC1 O15118 2/20 0.40
ADORA2A P29274 2/20 0.40
ADORA1 P30542 1/20 0.40
APEX1 P27695 1/20 0.40
GAA P10253 3/20 0.40
RAB9A P51151 1/20 0.40
HTR5A P47898 1/20 0.39
PIN1 Q13526 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MGAM O43451 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
POLB P06746 1/20 0.37
PTGS1 P23219 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036520 0.87 MBNL1 (0.39) MBNL1PDK1MAPTSMN1; SMN2TP53
SCHEMBL25551944 0.87 MBNL1 (0.39) MBNL1PDK1MAPTSMN1; SMN2TP53
SCHEMBL15944113 0.84 NPC1 (0.43) MBNL1MAPTNPC1ADORA2AADORA1
SCHEMBL30036735 0.83 RPS6KA5 (0.47) MBNL1MAPTNPC1ADORA2AADORA1
SCHEMBL25552080 0.83 MBNL1 (0.54) MBNL1MAPTSMN1; SMN2TP53NPC1
SCHEMBL25551811 0.83 RPS6KA5 (0.47) MBNL1MAPTNPC1ADORA2AADORA1
SCHEMBL30036973 0.83 MBNL1 (0.54) MBNL1MAPTSMN1; SMN2TP53NPC1
SCHEMBL25559456 0.80 NPC1 (0.40) MBNL1MAPTNPC1ADORA2AADORA1
SCHEMBL22529467 0.80 KMT2A (0.44) PDK1MAPTSMN1; SMN2GAAALDH1A1
SCHEMBL30037130 0.78 MBNL1 (0.47) MBNL1PDK1NPC1RAB9AHTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 US disclosed
CN-115515940-A Inhibitors of receptor interacting protein kinase I for the treatment of disease 德州大学系统董事会 2022-12-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 MBNL1 1407/4885PDK1 845/4885MAPT 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.